| Website | cempra.com |
| Category | BioTech |
| Employees | |
| Founded | 1/06 |
| Description | Antibiotics Developer |
| Total | $78M |
| Series A, 4/06 | $22M |
| Series B, 7/07 | $10M |
| Series C, 6/09 Quaker BioVentures Devon Park BioVentures Aisling Capital InterSouth Partners Teachers' Private Capital I. Wistar Morris III | $46M |
Cempra seeks to discover and develop well-differentiated medicines that cure bacterial infections and improve the quality of life for those with chronic illnesses. The company balances near-term product development opportunities, including the macrolide CEM-101, while investing in future products from new technologies to derive the next generation of antibiotics.
